# Neuralink — Healthcare Investment Intelligence

> medical_device · Series E. MedFuel Intel profile as of 2026-06-12.

Neuralink is developing implantable brain-computer interfaces (BCIs) and describes its goal as creating a general-purpose, high-bandwidth interface to the brain. It received U.S. FDA approval for human clinical trials in May 2023 and later received Health Canada approval for its first clinical trial in Canada in November 2024.

## Key facts (as of 2026-06-12)
- Sector: medical_device
- Stage: Series E
- Website: https://neuralink.com

## MedFuel assessment
- Intelligence score: 0/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/neuralink-32. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.